Hemab Therapeutics (NASDAQ:COAG) Posts Earnings Results

Hemab Therapeutics (NASDAQ:COAG) posted its earnings results on Tuesday. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.07), FiscalAI reports.

Here are the key takeaways from Hemab Therapeutics’ conference call:

• Hemab initiated SOLARA, its pivotal Phase III trial of sutacimig in Glanzmann thrombasthenia, with about 75 participants and a single-arm design comparing bleed rates before and during treatment. The FDA recommended considering a randomized trial; Hemab says it believes the chosen design is appropriate, but the agency’s feedback leaves regulatory uncertainty.
• Hemab highlighted Phase II extension results for sutacimig in Glanzmann, including fewer treated bleeds for 92% of participants who bled during run-in and a 62% reduction in mean high-intensity treated bleed rate. The company also reported three grade 2 thromboembolic events in higher-exposure cohorts and/or participants with multiple risk factors; it selected a lower weekly dose for SOLARA.
• HMB-002 showed proof of mechanism in von Willebrand disease, with peak increases of about 2.5-fold in von Willebrand factor and factor VIII and durability that may support monthly dosing. Hemab said eight of nine evaluable patients had no treated bleeds in the 28 days after dosing, but noted the early observations were descriptive and the study was not designed to measure efficacy.
• Sutacimig’s early Factor VII deficiency data showed a greater-than-50% shortening of prolonged prothrombin time in two participants, with exposure maintained through day 22; updated data are expected at ASH. Hemab also began a Phase I trial of HMB-003 and reported preclinical monkey data showing a shift toward less severe menstrual bleeding, with initial human data expected in mid-2027.
• Hemab reported $430.2 million in cash, equivalents and marketable securities at September 30, and expects its cash to fund operations into 2029. Quarterly R&D and G&A expenses rose year over year as clinical programs advanced and personnel costs increased.

Hemab Therapeutics Trading Down 2.9%

Shares of NASDAQ COAG traded down $1.13 during mid-day trading on Thursday, hitting $38.20. The company’s stock had a trading volume of 8,983 shares, compared to its average volume of 397,830. Hemab Therapeutics has a one year low of $23.00 and a one year high of $55.42. The company has a fifty day simple moving average of $37.23. The stock has a market capitalization of $1.78 billion and a PE ratio of -1.54.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on COAG. Lifesci Capital began coverage on shares of Hemab Therapeutics in a research report on Monday. They set an “outperform” rating and a $65.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on shares of Hemab Therapeutics in a research report on Thursday, October 15th. They set an “overweight” rating and a $70.00 target price on the stock. Rodman & Renshaw assumed coverage on shares of Hemab Therapeutics in a research note on Monday, October 12th. They set a “buy” rating and a $56.00 price target on the stock. Wedbush raised their price target on shares of Hemab Therapeutics from $55.00 to $64.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings cut shares of Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, September 25th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $56.00.

Institutional Trading of Hemab Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp raised its position in shares of Hemab Therapeutics by 1,105.8% in the 3rd quarter. State Street Corp now owns 927,245 shares of the company’s stock valued at $28,596,000 after acquiring an additional 850,345 shares during the period. Russell Investments Group Ltd. bought a new stake in Hemab Therapeutics in the third quarter valued at approximately $46,000. Profund Advisors LLC bought a new stake in Hemab Therapeutics in the third quarter valued at approximately $246,000. China Universal Asset Management Co. Ltd. raised its holdings in Hemab Therapeutics by 77.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 6,400 shares of the company’s stock worth $209,000 after purchasing an additional 2,800 shares during the period. Finally, Opaleye Management Inc. acquired a new stake in Hemab Therapeutics in the second quarter worth $1,750,000.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company developing treatments for serious bleeding and thrombotic disorders, with a focus on conditions that have limited treatment options. Its research centers on therapies intended to help restore or regulate blood clotting. The company’s lead candidate, HMB-001, is an investigational bispecific antibody being developed for Glanzmann thrombasthenia, a rare inherited bleeding disorder. Hemab is also advancing research into additional disorders affecting hemostasis, the process that helps the body control bleeding.